Pancreatic Cancer Research

ResearcherKitasato University HospitalActive in the last 2 years

Kosuke Okuwaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3671-1299; OpenAlex author ID A5045772874. Sources: OpenAlex.

Their work

Papers
12 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 12

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. High likelihood of BRCA2 reversion mutation in pancreatic cancer post-platinum-based chemotherapy: a case study. First author DOI 10.1007/s13691-024-00715-0↗
  3. Efficacy of endoscopic ultrasound-guided tissue acquisition using stereo-microscopic on-site evaluation for possible comprehensive genome profile in patients w… Co-author DOI 10.1111/jgh.16478↗
  4. Effectiveness of endoscopic ultrasound-guided tissue acquisition with stereomicroscopic on-site evaluation for preoperative diagnosis of resectable or borderli… First author DOI 10.5946/ce.2023.277↗
  5. Pancreatic Cancer Cells May Adhere to the External Surface of the Puncture Needle After Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1097/mpa.0000000000002256↗
  6. Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. First author DOI 10.2169/internalmedicine.0900-22↗
  7. New image-processing technology for endoscopic ultrasound-guided fine-needle aspiration biopsy specimen evaluation in patients with pancreatic cancer. Co-author DOI 10.1002/deo2.21↗
  8. Multicenter prospective study of the efficacy of stereomicroscopic on-site evaluation in endoscopic ultrasound-guided tissue acquisition in patients with pancr… First author DOI 10.1016/j.pan.2021.12.011↗
  9. A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer. First author DOI 10.1007/s10147-019-01511-0↗
  10. Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue o… Co-author DOI 10.1016/j.pan.2019.02.010↗
  11. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. Co-author DOI 10.1111/cas.14134↗
  12. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report]. Co-author PMID 28223678↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Watanabe · 9 shared papers, 2019–2024 · strength 1.38
  2. Chika Kusano · 6 shared papers, 2022–2024 · strength 1.08
  3. Takahiro Kurosu · 7 shared papers, 2019–2024 · strength 0.97
  4. Rikiya Hasegawa · 6 shared papers, 2019–2024 · strength 0.88
  5. Kai Adachi · 5 shared papers, 2019–2024 · strength 0.82
  6. Junro Ishizaki · 4 shared papers, 2022–2024 · strength 0.69
  7. Akihiro Tamaki · 4 shared papers, 2022–2024 · strength 0.65
  8. Taro Hanaoka · 3 shared papers, 2024 · strength 0.60
  9. Masayoshi Tadehara · 3 shared papers, 2019–2024 · strength 0.41
  10. Yusuke Kumamoto · 3 shared papers, 2017–2024 · strength 0.35
  11. Wasaburo Koizumi · 3 shared papers, 2019–2022 · strength 0.30
  12. Nobuyuki Nishizawa · 2 shared papers, 2019–2024 · strength 0.29
  13. Ayana Ishizaki · 1 shared paper, 2023 · strength 0.17
  14. Masahiko Watanabe · 2 shared papers, 2017–2019 · strength 0.14
  15. Keishi Yamashita · 1 shared paper, 2019 · strength 0.08
  16. Shuji Nakamoto · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.